Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum
Public ClinicalTrials.gov record NCT04518228. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study was to evaluate the pharmacokinetic (PK) properties of antiretroviral (ARV) and anti-tuberculosis (TB) drugs administered during pregnancy and postpartum.
Study identification
- NCT ID
- NCT04518228
- Recruitment status
- Terminated
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 205 participants
Conditions and interventions
Conditions
Interventions
- Bictegravir (BIC) Drug
- Tenofovir alafenamide (TAF) Drug
- Long-acting injectable formulation of cabotegravir (CAB LA) Drug
- Dolutegravir (DTG) Drug
- Atazanavir/ritonavir (ATV/r) Drug
- Darunavir/ritonavir (DRV/r) Drug
- Lopinavir/ritonavir (LPV/r) Drug
- Cobicistat Drug
- Ritonavir Drug
- First-Line TB Treatment Drug
- Second-Line TB Treatment Drug
- Doravirine (DOR) Drug
Drug
Eligibility (public fields only)
- Age range
- Not listed
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2021
- Primary completion
- Apr 23, 2025
- Completion
- Jul 9, 2025
- Last update posted
- Aug 25, 2026
2021 – 2025
United States locations
- U.S. sites
- 13
- U.S. states
- 7
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Usc La Nichd Crs | Los Angeles | California | 90033 | — |
| David Geffen School of Medicine at UCLA NICHD CRS | Los Angeles | California | 90095-1752 | — |
| University of California, UC San Diego CRS- Mother-Child-Adolescent HIV Program | San Diego | California | 92103 | — |
| Univ. of Colorado Denver NICHD CRS | Aurora | Colorado | 80045 | — |
| South Florida CDTC Ft Lauderdale NICHD CRS | Fort Lauderdale | Florida | 33316 | — |
| University of Florida Jacksonville NICHD CRS | Jacksonville | Florida | 32209 | — |
| Pediatric Perinatal HIV NICHD CRS | Miami | Florida | 33136 | — |
| Emory University School of Medicine NICHD CRS | Atlanta | Georgia | 30322 | — |
| Rush University Cook County Hospital Chicago NICHD CRS | Chicago | Illinois | 60612 | — |
| Lurie Children's Hospital of Chicago (LCH) CRS (Site ID: 4001) | Chicago | Illinois | 60614 | — |
| Johns Hopkins Univ. Baltimore NICHD CRS | Baltimore | Maryland | 21287 | — |
| Bronx-Lebanon Hospital Center NICHD CRS | The Bronx | New York | 10457 | — |
| Jacobi Med. Ctr. Bronx NICHD CRS | The Bronx | New York | 10461 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04518228, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 25, 2026 · Synced Sep 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04518228 live on ClinicalTrials.gov.